Stevanato Group targets €1.308B revenue in 2026. The pharmaceutical packaging and drug delivery company outlined ambitious growth plans during its Q4 2025 earnings call, projecting high-value solutions will comprise 48 percent of total sales by next year. This strategic shift reflects strong demand for specialized products including GLP-1 injection devices and Nexa syringes, which have emerged as key growth drivers. The company expects margin expansion as premium offerings scale. Stevanato's 2026 guidance signals confidence in sustained momentum across its portfolio, particularly in the booming GLP-1 market segment. Investors should monitor execution risks and competitive pressures in pharmaceutical delivery systems.
Post from MarketNews_en
Log in to interact with content.